PEPG PepGen Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1835597 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY21.6%
TTM EPS YoY72.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-55.1%
ROA-46.1%
ROIC (approx.)-121.4%
Asset turnover—
Leverage & solvency
Liabilities / assets19.3%
Debt / equity0.00x
Current ratio8.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-6.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $71.04M | $76.48M |
| SG&A expense | $22.57M | $21.26M |
| Operating income | -$93.61M | -$97.74M |
| Pretax income | -$89.61M | -$90.60M |
| Income tax | $48,865 | -$617,000 |
| Net income | -$89.66M | -$89.98M |
| EBITDA | -$92.21M | -$96.24M |
| EPS (basic) | -2.12 | -2.85 |
| EPS (diluted) | -2.12 | -2.85 |
| Weighted avg. shares (diluted) | 42.22M | 31.58M |
| Balance sheet | ||
| Cash & equivalents | $60.51M | $49.42M |
| Short-term investments | $87.94M | $70.77M |
| Current assets | $150.96M | $123.76M |
| PP&E, net | $1.90M | $3.72M |
| Total assets | $173.91M | $150.88M |
| Current liabilities | $12.65M | $16.70M |
| Total liabilities | $26.46M | $32.26M |
| Shareholders' equity | $147.44M | $118.62M |
| Shares outstanding | 68.87M | 32.62M |
| Cash flow statement | ||
| Operating cash flow | -$81.64M | -$82.37M |
| Capital expenditure | $264,000 | $497,000 |
| Free cash flow | -$81.90M | -$82.87M |
| Investing cash flow | -$15.23M | -$37.67M |
| Financing cash flow | $107.98M | $88.75M |
| Depreciation & amortization | $1.40M | $1.50M |
| Stock-based compensation | $10.61M | $11.46M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.